1. Home
  2. KBDC vs GYRE Comparison

KBDC vs GYRE Comparison

Compare KBDC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KBDC
  • GYRE
  • Stock Information
  • Founded
  • KBDC 2021
  • GYRE 2002
  • Country
  • KBDC United States
  • GYRE United States
  • Employees
  • KBDC N/A
  • GYRE N/A
  • Industry
  • KBDC
  • GYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • KBDC
  • GYRE Health Care
  • Exchange
  • KBDC Nasdaq
  • GYRE Nasdaq
  • Market Cap
  • KBDC 1.1B
  • GYRE 897.1M
  • IPO Year
  • KBDC N/A
  • GYRE N/A
  • Fundamental
  • Price
  • KBDC $16.07
  • GYRE $7.49
  • Analyst Decision
  • KBDC Buy
  • GYRE
  • Analyst Count
  • KBDC 4
  • GYRE 0
  • Target Price
  • KBDC $16.38
  • GYRE N/A
  • AVG Volume (30 Days)
  • KBDC 136.2K
  • GYRE 188.1K
  • Earning Date
  • KBDC 08-11-2025
  • GYRE 08-12-2025
  • Dividend Yield
  • KBDC 11.77%
  • GYRE N/A
  • EPS Growth
  • KBDC N/A
  • GYRE N/A
  • EPS
  • KBDC N/A
  • GYRE 0.02
  • Revenue
  • KBDC N/A
  • GYRE $100,643,000.00
  • Revenue This Year
  • KBDC $193.84
  • GYRE $21.04
  • Revenue Next Year
  • KBDC $12.68
  • GYRE $89.64
  • P/E Ratio
  • KBDC N/A
  • GYRE $96.96
  • Revenue Growth
  • KBDC N/A
  • GYRE N/A
  • 52 Week Low
  • KBDC $13.93
  • GYRE $6.11
  • 52 Week High
  • KBDC $17.99
  • GYRE $19.00
  • Technical
  • Relative Strength Index (RSI)
  • KBDC N/A
  • GYRE 42.81
  • Support Level
  • KBDC N/A
  • GYRE $7.49
  • Resistance Level
  • KBDC N/A
  • GYRE $7.80
  • Average True Range (ATR)
  • KBDC 0.00
  • GYRE 0.48
  • MACD
  • KBDC 0.00
  • GYRE 0.07
  • Stochastic Oscillator
  • KBDC 0.00
  • GYRE 40.48

About KBDC Kayne Anderson BDC Inc. Common Stock

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: